For this purpose, we engineered doxycycline-inducible shRNA vectors targeting MELK, which we transduced into MCF10A, BT-20, and MDA-MB-231 cells as the latter two breast cancer cell lines overexpress MELK with MCF10A cells as a control. The gene discussed is MELK; the disease is breast carcinoma.